{
    "id": 6771,
    "fullName": "IGF1R over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "IGF1R over exp indicates an over expression of the Igf1r protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3480,
        "geneSymbol": "IGF1R",
        "terms": [
            "IGF1R",
            "CD221",
            "IGFIR",
            "IGFR",
            "JTK13"
        ]
    },
    "variant": "over exp",
    "createDate": "05/29/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3953,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon carcinoma cells were sensitive to GSK1904529A in both culture and xenograft models, resulting in cell cycle arrest, decreased phosphorylation of Igf1r, and inhibition of tumor growth (PMID: 19383820).",
            "molecularProfile": {
                "id": 6626,
                "profileName": "IGF1R over exp"
            },
            "therapy": {
                "id": 2743,
                "therapyName": "GSK1904529A",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2857,
                    "pubMedId": 19383820,
                    "title": "Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19383820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3353,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, MM-141, in combination with Abraxane (nab-paclitaxel) and gemcitabine, displayed safety and preliminary efficacy in a variety of solid tumors with Erbb3 (Her3) and Igf1r overexpression (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT237).",
            "molecularProfile": {
                "id": 13273,
                "profileName": "ERBB3 over exp IGF1R over exp"
            },
            "therapy": {
                "id": 1249,
                "therapyName": "Gemcitabine + MM-141 + Nab-paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3758,
                    "pubMedId": null,
                    "title": "Preclinical characterization and first-in-human study of MM-141, a dual antibody inhibitor of IGF-1R and ErbB3",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/CT237?cited-by=yes&legid=canres;75/15_Supplement/CT237"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6093,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prolonged exposure to Alecensa (alectinib) resulted in acquired resistance through over-expression of IGF1R and NRG1, and loss of EML4-ALK in a non-small cell lung carcinoma cell line originally harboring EML4-ALK in culture (PMID: 26719536).",
            "molecularProfile": {
                "id": 22703,
                "profileName": "IGF1R over exp NRG1 over exp"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5313,
                    "pubMedId": 26719536,
                    "title": "Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26719536"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6095,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Linsitinib (OSI-906) and Tarceva (erlotinib) combination treatment inhibited growth of non-small cell lung carcinoma cell lines that acquired Alecensa (alectinib)-resistance through over-expression of IGF1R and NRG1 in culture (PMID: 26719536).",
            "molecularProfile": {
                "id": 22703,
                "profileName": "IGF1R over exp NRG1 over exp"
            },
            "therapy": {
                "id": 4041,
                "therapyName": "Erlotinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5313,
                    "pubMedId": 26719536,
                    "title": "Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26719536"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6626,
            "profileName": "IGF1R over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 5006,
                    "name": "IGF1R Antibody",
                    "profileName": "IGF1R over exp"
                },
                {
                    "id": 4997,
                    "name": "IGF-1R Inhibitor",
                    "profileName": "IGF1R over exp"
                },
                {
                    "id": 14014,
                    "name": "IGF1/2 Antibody",
                    "profileName": "IGF1R over exp"
                }
            ]
        },
        {
            "id": 13273,
            "profileName": "ERBB3 over exp IGF1R over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22703,
            "profileName": "IGF1R over exp NRG1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}